Cellular targeting is one way to actively target solely diseased tissue in the body is to know the nature of a receptor on the cell for which the drug will be targeted and then utilization of cell-specific ligands will allow the nanoparticle to bind specifically to the cell that has the complementary receptor.
Intracellular delivery enables efficient drug delivery into various types of cells and it is a long-term studied topic in modern biotechnology. It is a critical process in many cellular-level studies, such as cellular drug therapy, gene editing delivery, and a series of biomedical research applications.
Targeted Drug Delivery System:A targeted drug delivery system is a particular form of drug delivery where the drug is released specifically to its site of action and not to the target organs, tissues, or cells.
Drug Targeting and Design: Drug targeting can be defined as the ability of a drug molecule to accumulate in the target organ or tissue specifically, so that the concentration of the drug will be high at the disease, while in non-target organs and tissues, its concentration is low, preferably, below the certain minimal level so as to prevent any toxic effects. Drug targeting can control the non-specific toxic effect of conventional drug delivery.
Drug design is also known as rational drug design or simply rational design. It is a new process of producing new medications based on the knowledge of a biological target.
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, School of Health Sciences and Biomedical Engineering and Mansfield Bioincubator, China
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland